Shanghai Bio-heart Biological Technology Co., Ltd.

SEHK:2185 Stock Report

Market Cap: HK$433.3m

Shanghai Bio-heart Biological Technology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shanghai Bio-heart Biological Technology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth39.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Nov 15
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jul 24
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Feb 22
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Nov 03
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

May 12
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Sep 19
We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jun 03
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Bio-heart Biological Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2185 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-116-115-88N/A
3/31/2024N/A-146-91-68N/A
12/31/2023N/A-176-67-49N/A
9/30/2023N/A-182-117-96N/A
6/30/2023N/A-189-167-144N/A
3/31/2023N/A-197-169-142N/A
12/31/2022N/A-204-171-141N/A
9/30/2022N/A-234-149-113N/A
6/30/2022N/A-263-128-85N/A
3/31/2022N/A-312-125-87N/A
12/31/2021N/A-361-123-88N/A
9/30/2021N/A-437-108-83N/A
6/30/2021N/A-512-93-78N/A
3/31/2021N/A-419-74-63N/A
12/31/2020N/A-326-54-48N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2185's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2185's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2185's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2185's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2185's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2185's Return on Equity is forecast to be high in 3 years time


Discover growth companies